Cat: IPD-X12935

Recombinant Human VEGF121 Protein

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • Gene name

    VEGF121

  • 简介

    VEGF121 Protein, Human (120 a.a), a VEGF isoform splice variant, cannot bind to heparin. VEGF121 Protein is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers.

  • Application

    SPRMSTBLIITCELISACELL ASSAYDRUG SCREENING

  • Biological Activity

    1. The ED50 is ≤7.548 ng/mL as measured by HUVEC cells, corresponding to a specific activity of ≥1.32 × 105 units/mg. 2. Immobilized Human VEGF 121 at 2 μg/mL (100 μl/well) can bind Human VEGFR2-Fc.The ED50 of Human VEGFR2-Fc is ≤78 ng/mL. 3. Loaded Zifibancimig (HY-P990689) on FAB2G biosensor, can bind VEGF121 Protein, Human (120 a.a) with an affinity constant of <1.000E-11 M as determined in BLI assay. Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 7.474 ng/mL, corresponding to a specific activity is 1.34×105 units/mg. Loaded Zifibancimig (HY-P990689) on FAB2G biosensor, can bind VEGF121 Protein, Human (120 a.a) with an affinity constant of <1.000E-11 M as determined in BLI assay.

  • Alternative Names

    VEGF-AA; rHuVEGF-121; VPF

  • Species

    Human

  • Source

    E. coli

  • Tag

    Tag Free

  • Purity

    Greater than 95% as determined by reducing SDS-PAGE.

  • Uniprot

    P15692-9

  • Expression Region

    P28-R147

  • Protein Length

    Partial

  • Molecular Weight

    17 kDa under reduced (R) conditions, 28 kDa under non reducing (N) conditions, based on SDS-PAGE.

  • Endotoxin

    < 1.0 EU per μg protein as determined by the LAL method.

  • Form

    Freeze-dried powder

  • Buffer formulation

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • Reconstitution

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • Customization

    Site-directed mutagenesis Custom tag design Custom buffer formulation Custom full-length protein production

  • Stability Test

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • Storage & Shelf Life

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • Shipping

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

Vascular Endothelial Growth Factor (VEGF) plays a critical role in angiogenesis, the process of new blood vessel formation, which is essential for both normal physiology and pathological conditions such as cancer. Among its various isoforms, VEGF121 is a particularly interesting recombinant protein due to its unique biological properties. Unlike other VEGF isoforms, VEGF121 lacks a heparin-binding domain, allowing it to diffuse freely and exert its effects over a longer range, making it a prime candidate for targeted therapies aimed at enhancing angiogenesis in ischemic diseases or promoting tissue regeneration. Research has shown that VEGF121 can stimulate endothelial cell proliferation and migration, thus paving the way for improved vascularization. Furthermore, its application in therapeutic contexts has been investigated, including gene therapy and protein replacement strategies for conditions characterized by insufficient blood supply, such as peripheral artery disease and heart ischemia. Understanding the precise mechanisms by which VEGF121 operates and optimizing its delivery systems are pivotal for developing effective treatments that harness its angiogenic potential while minimizing the risk of tumor growth associated with excessive angiogenesis. Overall, studying VEGF121 not only provides insights into the fundamental processes of vascular development but also holds great promise for innovative therapeutic approaches in regenerative medicine and oncology.

E-mail

sales@ipodix.com

Sales

+1 2092920560


Contact us via WhatsApp

IPODIX Biotech Inc

2108 N ST, STE N
Sacramento, CA 95816, USA

For Product Information and Orders

sales@ipodix.com

For Business Collaboration

sales@ipodix.com

For CRO Services

sales@ipodix.com

For Technical Support

sales@ipodix.com
  • 50000+

    Recombinant Proteins

  • 100+

    Researchers

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US